Loading
Ariceum Therapeutics is a Berlin company that was developing a treatment carrying the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial was stopped after two patients, which the trial record puts down to business decisions.
Ariceum Therapeutics is a Berlin-based targeted radiotherapeutics company. Its lead candidate 225Ac-SSO110 is an actinium-225 labelled radioligand for extensive-stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma (MCC). The phase 1/2 SANTANA-225 study (NCT06939036) was planned to start in the second half of 2025, with initial safety data expected in early 2026 and preliminary efficacy findings in 2027. Its ClinicalTrials.gov record, last updated in February 2026, lists the study as terminated after enrolling 2 patients, with the reason given as strategic business decisions. In August 2025 David Schilansky, previously CFO, succeeded co-founder Manfred Rüdiger as CEO alongside a new executive team.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Small-cell lung cancer.
Shares Radioligand therapy (beta emitters), Small-cell lung cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/